Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Hosted on MSN1mon
Study Finds Exenatide Not Beneficial for Parkinson DiseaseFRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield ... receive extended-release exenatide 2 mg by subcutaneous pen injection once ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...
AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...
Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...
Study participants (n=194) were randomly assigned 1:1 to receive subcutaneous exenatide extended-release 2mg or placebo once weekly for 96 weeks. The primary endpoint was the Movement Disorder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results